Efficacy and Safety of Inhaled Recombinant Interleukin-2 in High-Risk Renal Cell Cancer Patients Compared with Systemic Interleukin-2: an Outcome Study Articles by the same authors

Fol. Biol. 2003, 49, 183-190

https://doi.org/10.14712/fb2003049050183

Efficacy and Safety of Inhaled Recombinant Interleukin-2 in High-Risk Renal Cell Cancer Patients Compared with Systemic Interleukin-2: an Outcome Study

Edith Huland¹, A. Burger², J. Fleischer³, P. Fornara⁴, E. Hatzmann⁵, A. Heidenreich⁶, H. Heinzer¹, H. Heynemann⁴, L. Hoffmann⁷, R. Hofmann⁶, H. Huland¹, I. Kämpfer⁷, M. Kindler², H. Kirchner⁸, G. Mehlhorn⁹, T. H. Moniak⁹, U. Rebmann⁹, J. Roigas¹⁰, T. H. Schneider⁴, D. Schnorr¹⁰, H.-J. Schmitz³, R. Wenisch³, Z. Varga⁶, J. Vinke⁵

¹Department of Urology, University Hospital Hamburg-Eppendorf, Germany
²Onkologische Schwerpunktpraxis, Berlin, Germany
³St. Carolus Krankenhaus, Görlitz, Germany
⁴Martin-Luther-Universität Halle-Wittenberg, Halle, Germany
⁵Chiron BV, Amsterdam
⁶Philipps-Universität Marburg, Marburg, Germany
⁷Waldklinikum GmbH, Gera, Germany
⁸Klinikum Siloah, Germany
⁹Diakonissenkrankenhaus, Dessau, Germany
¹⁰Department of Urology, Charite, Humboldt Universität Berlin, Germany

Received October 2003
Accepted October 2003

Folia Biologica
Journal of Cellular and Molecular Biology, Charles University

Fol. Biol. 2003, 49, 183-190

Efficacy and Safety of Inhaled Recombinant Interleukin-2 in High-Risk Renal Cell Cancer Patients Compared with Systemic Interleukin-2: an Outcome Study

Individual author index pages

Other articles of these authors

Archive